Sawaya et al. (2012) reported the utility of hs-TnI to predict trastuzumab induced
cardiotoxicity. Their report showed that elevated hs-TnI levels at 3 months after the completion of anthracycline therapy could predict subseq ent cardiotoxicity in
breast cancer patients with adjuvant trastuzumab therapy, and that hs-TnI with a cutoff value of 30 pg/mL had 48% sensitivity and 73% specificity for detecting cardiotoxicity.
Katsurada et al.(SpringerPlus 2014,3:620 http://www.springerplus.com/content/3/1/620) revealed both the hs-TnT levels and the hs-TnI levels not only at 3 months but also at 6 months were significantly higher than the corresponding values at baseline.
In most studies this is the timing of the baseline, 12 and 36 weeks
See more: ESC POSITION PAPER 2016: Eur Heart J (2016) 37 (36): 2768-2801- doi:10.1093/eurheartj/ehw2112016 CANCER TREATMENTS & CARDIOVASCULAR TOXICITY 2016 (POSITION PAPER)This document reviews the different steps in cardiovascular monitoring and decision-makig before, during and after anticancer treatment with potential cardiovascular side-effects.
If somebody working in onco-cardiology unit and has good experience in biomarkers it will be OK to discuss about hs NTproBNP and hs TnT. How we us in real clinical practice?
Hello everybody, my question in still open. In the accessible literature there are no clear recommendations to whom, when, through what terms to monitor biomarkers...